Related Experiment Video
Updated: May 11, 2026

09:04
Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells
Published on: May 22, 2014
Human astrocytes express a novel NLRP2 inflammasome
Julia Minkiewicz1, Juan Pablo de Rivero Vaccari, Robert W Keane
1Department of Physiology and Biophysics, University of Miami Miller School of Medicine, Miami, Florida 33136, USA.
Glia
|April 30, 2013
Summary
Extracellular ATP activates the NLRP2 inflammasome in astrocytes, driving central nervous system (CNS) inflammation after injury. Inhibiting this pathway may offer therapeutic benefits for CNS trauma.
Area of Science:
- Neuroscience
- Immunology
- Cell Biology
Background:
- Central nervous system (CNS) trauma triggers inflammation partly via extracellular ATP.
- Pattern recognition receptors (PRRs), including NOD-like receptors (NLRs), regulate innate immune responses.
- Glial cell signaling in CNS injury response is not fully understood.
Purpose of the Study:
- To investigate the role of the NLRP2 inflammasome in human astrocytes during CNS injury.
- To identify signaling pathways involved in ATP-induced astrocyte activation.
Main Methods:
- Stimulation of human astrocytes with extracellular ATP.
- Analysis of NLRP2 inflammasome complex formation and activation.
- Assessment of caspase-1 and IL-1β processing.
- Use of P2X7 receptor antagonist (BBG) and pannexin 1 inhibitor (probenecid).
- siRNA knockdown of NLRP2.
Main Results:
- Human astrocytes express and activate the NLRP2 inflammasome in response to ATP.
- ATP stimulation led to caspase-1 and IL-1β maturation.
- NLRP2 inflammasome activation was dependent on P2X7 receptor and pannexin 1 channel.
- Inhibition of P2X7 receptor or pannexin 1 channel blocked inflammasome activation.
- NLRP2 knockdown reduced ATP-induced caspase-1 processing.
Conclusions:
- The astrocytic NLRP2 inflammasome is activated by extracellular ATP, contributing to CNS inflammation.
- The NLRP2 inflammasome represents a potential therapeutic target for mitigating CNS inflammatory responses.
